Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE versus VIBERZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE versus VIBERZI.
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE vs VIBERZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate is a synthetic opioid agonist that acts on mu-opioid receptors in the gastrointestinal tract to reduce peristalsis and prolong transit time. Atropine is added in subtherapeutic doses to discourage intentional overdose and provides anticholinergic effects.
Guanylate cyclase-C agonist; increases intracellular cyclic guanosine monophosphate (cGMP) leading to activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid secretion and accelerated transit.
Each tablet contains diphenoxylate HCl 2.5 mg and atropine sulfate 0.025 mg. Adults: 2 tablets orally 4 times daily until diarrhea controlled, then reduce dose. Maximum 8 tablets per day for 2 days.
100 mg orally three times daily with meals.
None Documented
None Documented
Diphenoxylate: 2.5-12 hours (parent drug); difenoxin (active metabolite): 12-14 hours. Atropine: 2-4 hours. Clinical context: extended half-life of difenoxin allows twice-daily dosing for antidiarrheal effect.
Terminal elimination half-life is approximately 8-9 hours, supporting twice-daily dosing.
Diphenoxylate is primarily excreted in feces via biliary elimination (approx. 50%) and renal excretion (approx. 50% as metabolites); atropine is mainly excreted renally (30-50% unchanged and metabolites).
Primarily fecal (approximately 95% of absorbed dose) with minimal renal excretion (<1%).
Category C
Category C
Antidiarrheal
Antidiarrheal